DJIA 18,030.21 6.04 0.03%
NASDAQ 4,773.47 8.05 0.17%
S&P 500 2,081.88 -0.29 -0.01%
market minute promo

MannKind Corp (NASDAQ: MNKD)

5.67 0.17 (3.09%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

MNKD $5.67 3.09%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.52
Previous Close $5.50
Daily Range $5.50 - $5.71
52-Week Range $3.80 - $11.48
Market Cap $2.3B
P/E Ratio -9.48
Dividend (Yield) $0.00 (0.0%)
Volume 1,814,602
Average Daily Volume 4,038,144
Current FY EPS -$0.46





MannKind Corp (MNKD) Description

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer. Website:

News & Commentary

Buying These 3 Stocks Is Like Making a Bet in a Burning House

Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?

MannKind Corporation: An Analysis

Eli Lilly-Adocia Strike Deal to Develop Ultra-Rapid Insulin - Analyst Blog

Could the Next Generation of Diabetes Treatments Be Found in This Illegal Drug?

Diabetes affects more than 29 million Americans and can lead to a number of serious complications. However, this currently illegal drug could provide a new pathway for diabetics to achieve better glycemic balance.

A New Study on Diabetes Reveals Potentially Frightening News

Diabetes affects 29.1 million people in the United States, and is a dangerous long-term disease in its own right. This latest study, however, could add another aspect for diabetics to worry about.

Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)

3 Companies Growing Faster Than MannKind Corporation

MannKind may be on the precipice of growth surge thanks to Afrezza, but these three biotech stocks are still growing faster than MannKind.

4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst Blog

3 Healthcare Stocks to Watch in 2015

These are the three healthcare stocks you need to be watching heading into next year.

Is MannKind Corporation in Bed With Crooks? And Should Investors Care?

MannKind's marketing partner, Sanofi, may be in big trouble.

See More MNKD News...

MNKD's Top Competitors

MNKD $5.67 (3.09%)
Current stock: MNKD
AMGN $160.67 (2.00%)
Current stock: AMGN
GILD $91.15 (1.90%)
Current stock: GILD
BIIB $340.89 (1.53%)
Current stock: BIIB